Description
CJC-1295 No DAC at a glance
CJC-1295 No DAC is the catalog name for a modified 29-residue fragment of growth-hormone-releasing hormone, often called Mod GRF (1–29): GRF(1–29) with four amino-acid substitutions, but without the albumin-binding DAC linker that defines long-acting CJC-1295. Nearly all published human CJC-1295 data come from the DAC form. Ellepeptides lists the No DAC compound among its research peptides in a single 10 mg vial.
- Molecule type: modified GRF(1–29) analogue acting on the GHRH receptor; no DAC
- Vial size: 10 mg (single option)
- Listed price: from $110.00 USD per 10 mg vial
- Form: freeze-dried (lyophilized) powder
- Shipping: within the United States; free shipping once merchandise tops $200
- Use: for laboratory research only
CJC-1295 No DAC vial size and price per mg
| Vial size | Listed price (USD) | Price per mg |
|---|---|---|
| 10 mg | $110.00 | $11.00 |
With one size listed, the per-milligram figure is simply $110.00 ÷ 10, current at the time of writing; the product selector shows any update. Combination or multi-vial pricing through the cart or coupons is not promised.
CJC-1295 No DAC compound profile
| Listed compound | CJC-1295 No DAC |
|---|---|
| Other names in research use | Modified GRF (1–29); Mod GRF 1-29; tetrasubstituted GHRH(1–29)-NH2 |
| Research family | Growth-hormone-releasing hormone (GHRH) analogues |
| Core substitutions described in the literature | D-Ala2, Gln8, Ala15 and Leu27 relative to GRF(1–29) |
| What “No DAC” excludes | The C-terminal maleimido-lysine group that binds serum albumin |
| Molecular reference constants | The No DAC catalog name alone does not verify a sequence, CAS, formula or molar mass for this material. Values for albumin-binding CJC-1295 are not substituted. |
These rows describe how the literature defines the fragment and what the No DAC label leaves out. They are not an identity or composition result for a Ellepeptides lot; request material documentation if the exact sequence matters.
How CJC-1295 No DAC works in research
Like sermorelin, the modified fragment acts on the GHRH receptor of the anterior pituitary, prompting release of the gland’s own growth hormone. Native GRF(1–29) clears within minutes: in 10 healthy men its plasma half-life was 4.3 minutes, and putting D-alanine at position 2 extended that to 6.7 minutes while nearly halving clearance (Soule et al., 1994). The CJC-1295 core carries that same D-Ala2 plus three further substitutions, and its albumin-conjugated versions proved more stable against the enzyme dipeptidyl peptidase-IV in vitro (Jetté et al., 2005).
DAC is what changes the pharmacokinetics. The maleimido-lysine on long-acting CJC-1295 bonds covalently to cysteine 34 of serum albumin; in rats the compound persisted in plasma beyond 72 hours (Jetté et al., 2005), and in healthy adults its estimated half-life was 5.8 to 8.1 days (Teichman et al., 2006). Neither figure applies without the linker, and no peer-reviewed human half-life for the No DAC fragment was identified.
Key CJC-1295 studies and what they mean for No DAC
| Year | Study & model | What was measured | Main finding | Source |
|---|---|---|---|---|
| 1994 | 10 healthy men; GRF(1–29)-NH2 vs its D-Ala2 analogue | Plasma half-life; metabolic clearance | 4.3 min vs 6.7 min; clearance 39.7 vs 21 mL/kg·min | Soule et al. |
| 2005 | Rat pituitary cells; male Sprague Dawley rats (DAC form) | GH secretion; plasma persistence; DPP-IV stability | 4-fold GH area under the curve over 2 h vs unconjugated hGRF(1–29); present beyond 72 h | Jetté et al. |
| 2006 | Two placebo-controlled trials; healthy adults aged 21–61 (DAC form) | GH, IGF-I, half-life, tolerability | GH up 2- to 10-fold for 6+ days; IGF-I up 1.5- to 3-fold for 9–11 days; half-life 5.8–8.1 days | Teichman et al. |
| 2006 | Healthy men aged 20–40 (DAC form) | GH pulsatility, trough GH, IGF-I | Pulse frequency and size unchanged; trough GH 7.5-fold; mean GH +46%; IGF-I +45% | Ionescu & Frohman |
Three of the four rows describe CJC-1295 with DAC. They are the CJC-1295 literature, and they show what the DAC linker contributes. The Soule study is the only row about an unconjugated GRF(1–29) analogue in people, and it tested a single substitution rather than the full tetrasubstituted fragment.
The Teichman trials reported no serious adverse reactions and called the DAC compound relatively well tolerated (Teichman et al., 2006). Ionescu and Frohman found that GH pulses kept their frequency and size under continuous stimulation, with the rise in mean GH driven by higher troughs (Ionescu & Frohman, 2006). Neither finding transfers to the No DAC fragment, which lacks the albumin-binding group behind that sustained exposure. More context sits in the Ellepeptides research library.
CJC-1295 No DAC research involving women
Women and men took part in both Teichman trials, as the published participant table shows, but every participant received the long-acting DAC compound (Teichman et al., 2006). The GH-pulse study enrolled men only.
No clinical or animal study of the No DAC fragment in females was identified. For female-focused models the gap is complete: half-life, GH response and adverse-event rates of the No DAC form are uncharacterized in women. Other compounds relevant to that work are collected under peptides for women.
CJC-1295 No DAC vs CJC-1295 with DAC, sermorelin and ipamorelin
| Compound | Type | Receptor studied | Main research focus | Published half-life | Sizes on Ellepeptides |
|---|---|---|---|---|---|
| CJC-1295 No DAC | Tetrasubstituted GRF(1–29), no DAC | GHRH receptor | Little direct published research | No peer-reviewed human value found | 10 mg |
| CJC-1295 with DAC (reference only, not listed) | Tetrasubstituted GRF(1–29) + albumin-binding linker | GHRH receptor | Sustained GH and IGF-I rise (healthy adults) | 5.8–8.1 days | Not listed |
| Sermorelin | GHRH(1–29) amide | GHRH receptor | Growth in GH-deficient children; aging studies | About 4.3 min (healthy men) | 5 and 10 mg |
| Ipamorelin | Synthetic pentapeptide | Ghrelin receptor | Selective GH release (animals); bowel-recovery trial | About 2 h (healthy men) | 5 and 10 mg |
| CJC-1295 No DAC + Ipamorelin Blend | Two-component mixture | GHRH + ghrelin receptors | No study of this mixture | Not established | 5 mg + 5 mg |
The first two rows answer the DAC vs No DAC question. Both forms share the tetrasubstituted GRF(1–29) core; DAC adds the albumin-binding linker that lengthens the measured half-life to days, whereas unconjugated GRF(1–29) lasts minutes. Against sermorelin, the No DAC fragment differs by four residues. Ipamorelin acts through the ghrelin receptor instead, and Ellepeptides sells it both alone and in the 5 mg + 5 mg blend with this compound.
CJC-1295 No DAC handling, storage and reconstitution math
CJC-1295 No DAC is supplied as a dry, lyophilized solid. Storage instructions are whatever the label states; keep to those, and write to [email protected] if the label leaves a question open. Logging lot and reconstitution date keeps experiments traceable.
Because the vial holds 10 mg, concentration depends only on the solvent volume chosen: 10 mg in 2 mL is 5 mg/mL, and in 5 mL it is 2 mg/mL. The peptide calculator handles other volumes and units, and bacteriostatic water is listed separately. This is bench arithmetic, not guidance for use in people or animals.
Ordering CJC-1295 No DAC in the US
CJC-1295 No DAC orders ship to addresses within the United States. Shipping is free when the merchandise subtotal exceeds $200 after coupon discounts, before taxes and shipping. Otherwise, standard shipping is $15.99 per order. The available payment methods and delivery options are shown at checkout. Current details are in the shipping policy.
CJC-1295 No DAC FAQ
What is CJC-1295 No DAC (Mod GRF 1-29)?
It is a modified 29-residue fragment of growth-hormone-releasing hormone carrying four substitutions (D-Ala2, Gln8, Ala15, Leu27) and no DAC albumin-binding linker. The name Mod GRF (1–29) is often used for the same fragment. Ellepeptides lists it as freeze-dried research material in a 10 mg vial.
What is the difference between CJC-1295 with DAC and No DAC?
DAC is a maleimido-lysine linker that binds serum albumin covalently. With it, CJC-1295 had an estimated half-life of 5.8–8.1 days in healthy adults. Without it, the molecule is an unconjugated GRF(1–29) analogue whose human persistence has not been published. Ellepeptides lists only the No DAC form.
How much does CJC-1295 cost in the US?
Ellepeptides lists CJC-1295 No DAC at $110.00 USD for a 10 mg vial, about $11.00 per mg at the time of writing. The product selector always shows the current price. The blend with ipamorelin is priced separately on its own product page.
Where can I buy CJC-1295 in the US?
Ellepeptides lists CJC-1295 No DAC research vials that ship within the United States, priced in U.S. dollars, with payment methods shown at checkout. Orders with more than $200 of merchandise after coupons qualify for free shipping. Vials are supplied for laboratory work only, not personal use.
What is the half-life of CJC-1295?
It depends on the form. Long-acting CJC-1295 with DAC had an estimated half-life of 5.8–8.1 days in healthy adults. No peer-reviewed human half-life was found for the No DAC fragment; for comparison, unmodified GRF(1–29) lasted about 4.3 minutes and a D-Ala2 analogue about 6.7 minutes in healthy men.
What side effects were reported in CJC-1295 studies?
In the two Teichman trials of the DAC form, no serious adverse reactions were reported and the compound was described as relatively well tolerated. Those trials enrolled healthy adults aged 21 to 61. No published adverse-event data for the No DAC fragment were identified, so DAC findings should not be applied to it.
What are the benefits of CJC-1295 in research?
Studies of the DAC form measured hormone markers: after a single administration in healthy adults, GH rose 2- to 10-fold for six days or more and IGF-I 1.5- to 3-fold for 9–11 days. These are endocrine results, not shown changes in muscle, fat or sleep, and they do not describe No DAC.
Why is CJC-1295 paired with ipamorelin?
The two act on different receptors, GHRH and ghrelin, and an older study found that a GH-releasing peptide combined with GHRH released GH synergistically in healthy men. That study used different compounds; no published trial has tested CJC-1295 No DAC with ipamorelin. See the blend page for details.
Has CJC-1295 been studied in women?
Only the DAC form. Women participated in both Teichman trials, but no women-specific results were reported. No study of the No DAC fragment in women or female animals was identified, so female-specific data for this product do not yet exist and should not be inferred from DAC research.
Is CJC-1295 available as a nasal spray or capsules?
Ellepeptides offers CJC-1295 No DAC only as freeze-dried powder in a 10 mg vial. No nasal, oral or topical version is listed, and none of the cited studies evaluated such formats, so their findings should not be assumed to apply to them.
CJC-1295 No DAC references
- Jetté et al., 2005. hGRF(1–29)-albumin conjugates and CJC-1295. PubMed
- Teichman et al., 2006. Long-acting CJC-1295 in healthy adults. PubMed
- Soule et al., 1994. D-Ala2 and GHRH(1–29) half-life in men. PubMed
- Ionescu & Frohman, 2006. GH pulsatility during CJC-1295. PubMed
- Gobburu et al., 1999. Ipamorelin pharmacokinetics in healthy men. PubMed
- Bowers et al., 1990. GHRP and GHRH synergy in normal men. Oxford Academic
Related research materials: Muscle & Performance peptides, peptide blends, Ipamorelin, CJC-1295 No DAC + Ipamorelin Blend, Sermorelin and Tesamorelin. For laboratory research only. Not for human or veterinary use.
Reviews
There are no reviews yet.